EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies

Mohammadreza Afshari, Martina Řezáčová, Darina Muthná

Folia Biologica · 2026 · 72 (1) · 1-15

DOI: 10.14712/fb2026.0002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Folia Biologica, online erschienen am 26.03.2026. Verfasst von Mohammadreza Afshari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Karlova v Praze.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FMS-like tyrosine kinase 3 (FLT-3) mutations represent one of the most common genetic anomalies in acute myeloid leukaemia (AML), particularly in adults. The two most common types of mutations, internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations, facilitate uncontrolled cellular proliferation and unfavourable patient outcomes. These mutations are linked with a high relapse rate and shorter overall survival, highlighting the need for targeted therapies to be used. Recent advances in the discovery of new agents enabled incorporation of FLT-3 inhibitors into the frontline treatment regimen. First-generation inhibitors, such as midostaurin, provided the foundation for targeted therapy, while recently developed agents such as gilteritinib and quizartinib have shown more selectivity and demonstrated superior clinical efficiency and improved tolerability. This review discusses the significance of FLT-3 mutations, the evolution of targeted therapies, current treatment guidelines, and ongoing challenges such as resistance and high relapse rates. We also discuss the emerging combinations of therapies and novel agents currently in clinical trials that aim to overcome resistance and improve long-term outcomes for patients with FLT-3-mutated AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationHumansProtein Kinase InhibitorsMolecular Targeted TherapyAniline CompoundsPyrazines

Stichwörter der Autor:innen

FLT3-ITDacute myeloid leukaemiagilteritinibmidostaurintargeted therapytyrosine kinase inhibitors

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanProtein Kinase InhibitorsgilteritinibAniline CompoundsPyrazines

Autor:innen und Institutionen

  • Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
  • Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic. muthnad@lfhk.cuni.cz.

Förderung

  • Univerzita Karlova v Praze

Zitieren

APA

Afshari, M., Řezáčová, M., & Muthná, D. (2026). Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies. Folia Biologica, 72(1), 1-15. https://doi.org/10.14712/fb2026.0002

Vancouver

Afshari M, Řezáčová M, Muthná D. Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies. Folia Biologica. 2026;72(1):1-15. doi:10.14712/fb2026.0002

BibTeX
@article{Afshari2026,
  author = {Afshari, Mohammadreza and Řezáčová, Martina and Muthná, Darina},
  title = {Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies},
  journal = {Folia Biologica},
  year = {2026},
  volume = {72},
  number = {1},
  pages = {1--15},
  doi = {10.14712/fb2026.0002}
}
Kostenlos starten →